Apotex Holdings Inc. and Apotex Inc., Canadian companies in the pharmaceutical industry, have filed claims under the ICSID Additional Facility Rules for alleged injuries arising out of Import Alerts issued by the U.S. Food and Drug Administration concerning two of Apotex’s Canadian manufacturing facilities. Apotex seeks at least $520 million in damages for alleged violations of NAFTA Articles 1102 (national treatment), 1103 (most favored nation treatment), and 1105 (minimum standard of treatment).
-03/06/12
Notice of Arbitration
[1883 Kb]
-07/24/12
First Procedural Order (finalized on 11/29/2012)
[171 Kb]
-07/30/12
Claimants' Memorial
[8659 Kb]
-10/29/12
Second Procedural Order
[89 Kb]
-12/14/12
U.S. Counter-Memorial and Objections to Jurisdiction
[2036 Kb]
-12/28/12
Claimants' Opposition to Bifurcation
[895 Kb]
-01/10/13
U.S. Reply on Bifurcation
[313 Kb]
-01/16/13
Claimants' Rejoinder on Bifurcation
[954 Kb]
-01/25/13
Third Procedural Order
[1187 Kb]
-03/04/13
Procedural Order on the participation of applicant Mr. Barry Appleton as a non-disputing party
[65 Kb]
-03/04/13
Procedural Order on the participation of applicant BNM as a non-disputing party
[92 Kb]
